Results 21 to 30 of about 21,301 (157)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

BMC Cancer, 2023
Background There are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in
Hui Tang, Yuping Ge, Tingting You, Xiaoyuan Li, Yingyi Wang, Yuejuan Cheng, Chunmei Bai   +6 more
doaj   +1 more source

Loss of ETV4 triggers PPM1E downregulation and AMPK–ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer

Pharmacological Research
Trametinib, a selective MEK1/2 inhibitor, is approved for melanoma, BRAF-mutant non-small cell lung cancer, and thyroid cancer. Its favorable pharmacologic profile has prompted broader evaluation across cancers driven by MAPK/ERK signaling.
Xiaodong Liu, Su Hyeon Yu, Jiyoon Kang, Ji Won Kim   +3 more
doaj   +1 more source

Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Scientific Reports, 2021
Angiosarcoma is an aggressive malignancy of endothelial cells that carries a high mortality rate. Cytotoxic chemotherapy can elicit clinical responses, but the duration of response is limited.
Michael J. Wagner, Yasmin A. Lyons, Jean H. Siedel, Robert Dood, Archana S. Nagaraja, Monika Haemmerle, Lingegowda S. Mangala, Pritha Chanana, Alexander J. Lazar, Wei-Lien Wang, Vinod Ravi, Eric C. Holland, Anil K. Sood   +12 more
doaj   +1 more source

Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.

PLoS ONE, 2014
Cellular signaling pathways involving mTOR, PI3K and ERK have dominated recent studies of breast cancer biology, and inhibitors of these pathways have formed a focus of numerous clinical trials.
Euphemia Y Leung, Ji Eun Kim, Marjan Askarian-Amiri, Gordon W Rewcastle, Graeme J Finlay, Bruce C Baguley   +5 more
doaj   +1 more source

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer

Cancer Treatment and Research Communications, 2022
: OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer ...
Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quynh-Nhu Nguyen, Michael S O'Reilly, Charles Lu, Frank V Fossella, Ferdinandos Skoulidis, Jianjun Zhang, Anne S Tsao, John V Heymach, George R Blumenschein   +19 more
doaj   +1 more source

The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats

Pharmaceuticals, 2022
Aneurysmal subarachnoid haemorrhage (SAH) is a haemorrhagic stroke that causes approximately 5% of all stroke incidents. We have been working on a treatment strategy that targets changes in cerebrovascular contractile receptors, by blocking the MEK/ERK1 ...
Jesper Peter Bömers, Anne-Sofie Grell, Lars Edvinsson, Sara Ellinor Johansson, Kristian Agmund Haanes   +4 more
doaj   +1 more source

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment

Molecular Oncology, 2022
A more comprehensive understanding of how cells respond to drug intervention, the likely immediate signalling responses and how resistance may develop within different microenvironments will help inform treatment regimes.
John C. Dawson, Alison Munro, Kenneth Macleod, Morwenna Muir, Paul Timpson, Robert J. Williams, Margaret Frame, Valerie G. Brunton, Neil O. Carragher   +8 more
doaj   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Scientific Reports
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer.
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng   +12 more
doaj   +1 more source

Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report

Case Reports in Oncology, 2023
Sporadically occurring malignant peripheral nerve sheath tumours (MPNSTs) can have a variety of genomic alterations including altered NF1, leading to activation of the RAS-RAF-MEK-ERK signalling pathway. Trametinib is an inhibitor of MEK1 and MEK2.
Nadia Hitchen, Matthew Cross, George Laking, Joanna Connor, Clement Korenbaum   +4 more
doaj   +1 more source